Targeting T-cell costimulation to the surface of tumor cells

IF 10 1区医学 Q1 ONCOLOGY

Clinical Cancer Research Pub Date : 2024-11-12 DOI:10.1158/1078-0432.ccr-24-3003

Iñaki Eguren-Santamaría, Miguel F. Sanmamed, Paula Molero-Glez, Jose Luis Perez-Gracia, Ignacio Melero

引用次数: 0

Abstract

Bispecific agents targeting tumor-cell surface antigens and activating receptors on T lymphocytes are being developed for solid tumors. Effective and safe strategies depend on target specificity and at least relative tumor-tissue confinement of T-cell activation. Novel evidence suggests that constructs targeting HER2 on tumor cells with the aim of providing costimulation (signal-2) to T lymphocytes via CD137 (4-1BB) are safe and can meaningfully invigorate antitumor responses in a proportion of patients.

查看原文本刊更多论文

以肿瘤细胞表面的 T 细胞成本刺激为目标

目前正在开发针对肿瘤细胞表面抗原和 T 淋巴细胞活化受体的双特异性制剂，以治疗实体瘤。有效而安全的策略取决于靶点的特异性和 T 细胞激活至少在肿瘤组织间的相对封闭性。新证据表明，以肿瘤细胞上的 HER2 为靶点，通过 CD137（4-1BB）向 T 淋巴细胞提供成本刺激（信号-2）的构建物是安全的，并能有效激活一部分患者的抗肿瘤反应。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

Clinical Cancer Research 医学-肿瘤学

CiteScore

20.10

自引率

1.70%

发文量

1207

审稿时长

2.1 months

期刊介绍： Clinical Cancer Research is a journal focusing on groundbreaking research in cancer, specifically in the areas where the laboratory and the clinic intersect. Our primary interest lies in clinical trials that investigate novel treatments, accompanied by research on pharmacology, molecular alterations, and biomarkers that can predict response or resistance to these treatments. Furthermore, we prioritize laboratory and animal studies that explore new drugs and targeted agents with the potential to advance to clinical trials. We also encourage research on targetable mechanisms of cancer development, progression, and metastasis.